Zyla Life Sciences Watch

ended 03/31/20 Q1

ended 12/31/19 FY 2019 – amended

ended 12/31/19 FY 2019

ended 09/30/19 Q3

ended 06/30/19 Q2

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Business combination disclosure

Tekla Capital Management LLC

CRG Partners III L.P., CRG Partners III - Parallel Fund (A) L.P., CR Group L.P., CRG Partners III - Parallel Fund B (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., CRG Partners III (Cayman) Unlev AIV I L.P., Loan Security Holdings I LLC

CR Group L.P.

McInnis Joe

Strobeck Mark

Assertio Completed Merger With Zyla Life Sciences Trading Under ASRT on Nasdaq Global Select Market Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Upwards of $40 Million in Expected Cost Synergies

Termination of Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Shareholder Vote Results, Financial Statements or Exhibits

Q1 2020 Script

Reports First Quarter 2020 Financial Results

Change in Directors, Officers or Compensation, Other Events

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Notice of effectiveness

Notice of effectiveness

 

Correspondence with the SEC

Letter from the SEC